Moderna Reports Third Quarter 2023 Financial Results and Provides Business Updates
- Third quarter 2023 revenues of $1.8 billion; Company expects 2023 revenues of at least $6 billion
- Spikevax U.S. market share to date increased to 45% from 36% in 2022
- Company anticipates 2024 revenue of approximately $4 billion and return to growth in 2025
- Company has significantly improved future cost of sales by resizing its manufacturing capacity, contributing to a third quarter net loss of $3.6 billion, primarily driven by mostly non-cash charges of $3.1 billion related to resizing and a tax valuation allowance
- Company's late-stage pipeline has six Phase 3 programs
- Company expects to break even in 2026 through product launches and disciplined investment
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.